Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Operating Income (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Operating Income for 6 consecutive years, with $14.7 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 126.22% to $14.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$159.5 million through Dec 2025, up 15.06% year-over-year, with the annual reading at -$159.5 million for FY2025, 15.06% up from the prior year.
  • Operating Income for Q4 2025 was $14.7 million at 4D Molecular Therapeutics, up from -$61.2 million in the prior quarter.
  • The five-year high for Operating Income was $14.7 million in Q4 2025, with the low at -$61.2 million in Q3 2025.
  • Average Operating Income over 5 years is -$32.1 million, with a median of -$29.4 million recorded in 2022.
  • The sharpest move saw Operating Income tumbled 274.22% in 2022, then soared 126.22% in 2025.
  • Over 5 years, Operating Income stood at -$24.8 million in 2021, then fell by 15.97% to -$28.7 million in 2022, then fell by 27.62% to -$36.7 million in 2023, then crashed by 53.11% to -$56.1 million in 2024, then skyrocketed by 126.22% to $14.7 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at $14.7 million, -$61.2 million, and -$59.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.